Literature DB >> 26141741

[Depression in cancer patients].

Barbara Sperner-Unterweger1.   

Abstract

Cancer patients often suffer from major depression or depressive syndromes. Although it is well known that depressive symptoms can appear at any time during the course of an oncological disease, certain periods for instance time after diagnosis carry a higher risk. Reported prevalence rates differ widely (up to 60%), reflecting also diagnostic difficulties. Oncologists recognize depression in their patients only in 15 to 50% and the percentage of patients who receive adequate therapy is even lower. Consequently, this leads to a reduced quality of life. Furthermore, impaired compliance/adherence and consequently a poorer prognosis of the oncological disease are discussed in this context. It should be also emphasized, that concomitant depression increases the risk of suicide in cancer patients. Although the number of clinical trials using either psychotherapy or antidepressant medication for the therapy of depression in cancer patients is limited, good therapeutic options are available.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26141741     DOI: 10.1007/s10354-015-0363-8

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  47 in total

1.  Venlafaxine in neuropathic pain following treatment of breast cancer.

Authors:  Tiina Tasmuth; Brita Härtel; Eija Kalso
Journal:  Eur J Pain       Date:  2002       Impact factor: 3.931

Review 2.  Antidepressant medication use in palliative care.

Authors:  Karl E Miller; Stephen M Adams; Martha M Miller
Journal:  Am J Hosp Palliat Care       Date:  2006 Mar-Apr       Impact factor: 2.500

3.  Use of psychotropic medications by US cancer survivors.

Authors:  Rajeshwari S Punekar; Pamela Farley Short; John R Moran
Journal:  Psychooncology       Date:  2011-09-09       Impact factor: 3.894

4.  Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6.

Authors:  Robert L Walsky; Angela V Astuccio; R Scott Obach
Journal:  J Clin Pharmacol       Date:  2006-12       Impact factor: 3.126

5.  The association of depression and anxiety with health-related quality of life in cancer patients with depression and/or pain.

Authors:  Linda F Brown; Kurt Kroenke; Dale E Theobald; Jingwei Wu; Wanzhu Tu
Journal:  Psychooncology       Date:  2010-07       Impact factor: 3.894

6.  Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

Authors:  Vered Stearns; Michael D Johnson; James M Rae; Alan Morocho; Antonella Novielli; Pankaj Bhargava; Daniel F Hayes; Zeruesenay Desta; David A Flockhart
Journal:  J Natl Cancer Inst       Date:  2003-12-03       Impact factor: 13.506

Review 7.  Depression in cancer: new developments regarding diagnosis and treatment.

Authors:  Charles L Raison; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2003-08-01       Impact factor: 13.382

Review 8.  Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.

Authors:  Janyce F Rogers; Anne N Nafziger; Joseph S Bertino
Journal:  Am J Med       Date:  2002-12-15       Impact factor: 4.965

9.  Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial.

Authors:  Barbara L Andersen; Hae-Chung Yang; William B Farrar; Deanna M Golden-Kreutz; Charles F Emery; Lisa M Thornton; Donn C Young; William E Carson
Journal:  Cancer       Date:  2008-12-15       Impact factor: 6.860

10.  Management of major depression in outpatients attending a cancer centre: a preliminary evaluation of a multicomponent cancer nurse-delivered intervention.

Authors:  M Sharpe; V Strong; K Allen; R Rush; P Maguire; A House; A Ramirez; A Cull
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

View more
  1 in total

1.  A Descriptive Cohort of Suicidal Cancer Patients: Analysis of the Autopsy Case Series from 1993 to 2019 in Milan (Italy).

Authors:  Guendalina Gentile; Stefano Tambuzzi; Raffaella Calati; Riccardo Zoja
Journal:  Int J Environ Res Public Health       Date:  2022-01-12       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.